Allopurinol
Brand names: Allopurinol
At a glance
- Medicare prescriptions, 2024
- 8,924,221
- Medicare drug cost
- $88.8M
- Average cost per prescription
- $9.95
- Clinicians who prescribed it
- 179,443
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
Allopurinol Tablets is indicated for: The management of adults with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy) The management of adult and pediatric patients with leukemia, lymphoma and solid tumor malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels The management of adult patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800 mg/day in male patients and 750 mg/day in female patients, despite lifestyle changes (such as reduction of dietary sodium, non-dairy animal protein, oxylate rich foods, refined sugars and increases in oral fluids and fruits and vegetables) Limitations of Use Allopurinol Tablets is not recommended for the treatment of asymptomatic hyperuricemia.
From the FDA-approved prescribing information (label dated September 2026). Full labels on DailyMed (opens in a new tab)
Who prescribes it
- Family Medicine 35.5%
- Internal Medicine 29.3%
- Nurse Practitioners 14.2%
- Nephrology (Kidney) 4.9%
- Physician Assistants 4.8%
- Rheumatology 3.6%
- General Practice 1.5%
- Geriatric Medicine 1.5%
- Cardiology 0.7%
- Hematology & Oncology 0.6%
- Urology 0.5%
- Hospitalist 0.4%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2019–2024
Medicare prescriptions rose 8% from 2019 to 2024.
Biggest change by state since 2019
- Puerto Rico +32%
- Utah +22%
- Maryland +22%
- Delaware +18%
- New Hampshire +17%
- Rhode Island (smallest change) −2%
- Mississippi (smallest change) −1%
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
What it looks like
Pills from 5 makers on file. The same medicine can look different depending on who made it, so check the imprint (the letters and numbers on the pill) with your pharmacist if a refill looks different.
A-S Medication Solutions
| Strength | Looks like | Imprint |
|---|---|---|
| 100 mg | white capsule, 8 mm, scored to split in 2 | I 135 |
Accord Healthcare Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 100 mg | white round tablet, 8 mm, scored to split in 2 | AW |
| 300 mg | white round tablet, 11 mm, scored to split in 2 | AX |
Avpak
| Strength | Looks like | Imprint |
|---|---|---|
| 100 mg | white capsule, 8 mm, scored to split in 2 | I 135 |
| 300 mg | pink capsule, 11 mm, scored to split in 2 | I 136 |
Bryant Ranch Prepack
| Strength | Looks like | Imprint |
|---|---|---|
| 100 mg | white round tablet, 10 mm, scored to split in 2 | MP 71 |
Dr. Reddy's Laboratories Limited
| Strength | Looks like | Imprint |
|---|---|---|
| 100 mg | white round tablet, 10 mm, scored to split in 2 | 0524 0405 |
| 300 mg | white round tablet, 11 mm | AL3 |
Source: DailyMed (U.S. National Library of Medicine), from each maker’s FDA drug listing. A few makers are shown, not every one. Never take a pill you can’t identify; ask a pharmacist.
Industry payments about this drug
No industry payments to clinicians named this drug in 2025.
Recalls and shortages
Not on the FDA drug shortage list.
4 recalls since 2020
- Jun 2024 · Dr. Reddy's Laboratories, Inc. · Class II
Presence of foreign substance. - Jan 2023 · Accord Healthcare, Inc. · Class II
Presence of Foreign Substance: Presence of a small piece of green plastic embedded in the crack towards the edge of the tablet. - Jan 2022 · Cardinal Healthcare · Class II
CGMP Deviations: Products were exposed to temperatures outside of the products labeled storage conditions. - May 2020 · Mylan Institutional LLC · Class II
Discoloration: Out-of-specification results for appearance obtained during routine stability testing at the end of shelf-life for the parameters Appearance and Color of Solution.
Recalls usually affect specific lots from one maker, not every version of a drug. Class I is the most serious; most drug recalls are Class II. FDA recalls (opens in a new tab)
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.